Jun 11, 2020 / 01:40PM GMT
Ziyi Chen - Goldman Sachs Group, Inc., Research Division - Equity Analyst
Good morning, everyone. Thank you for joining today's Zai Lab session at our Global Healthcare Conference. This is Ziyi Chen, China healthcare analyst at Goldman Sachs.
Today joining us are Zai Lab's Co-Founder, Chairperson and CEO, Dr. Samantha Du; CFO, Billy Cho; and Jonathan Wang, Head of BD and IR team. Thank you all for attending these sessions.
Questions and Answers:
Ziyi Chen - Goldman Sachs Group, Inc., Research Division - Equity AnalystJust to start the session, here's one specific question that probably most investors will be highly interested is the impact of COVID-19. We actually start this question for each of the session. So could you please give us some thoughts on the impact on clinical trials, BD activities and also the commercial launch of ZEJULA, Optune in China in this environment, particularly in first quarter? And how we actually track the recovery of everything, gradually back to normal in May, June? So any thoughts on that?
Ying Du<